Drugs prices have been drawing attention recently following the decisions by various pharmaceutical companies to spike the cost of various medications several times their original price overnight.
Pharmaceutical companies have the upper hand in drug prices, because patients often have no recourse beyond their medication. But even with the high costs of some treatments, they can be a value compared with the long-term physical and financial burden of the illness itself, finds a study by University of California - San Francisco researchers.
Hepatitis C is a disease that can lead to liver cancer, transplants, cirrhosis and more, but that damage is preventable if treated early. Harvoni cures hepatitis C, but at a cost of $100,000 for the full course of treatment. Insurance companies typically only cover the cost of the treatment in the later stages of the disease, a practice that isn't as cost-effective, the researchers found.
More than 3 million people in the United States have hepatitis C, most of whom were infected from tainted blood transfusions received before 1992. Most new infections are the result of intravenous drug use.
Although $100,000 is no small sum, Harvoni doesn't rank among the most expensive drugs on the market today, many of which are meant to treat a much smaller pool of patients.

Made by Regeneron Pharmaceuticals, Arcalyst is a treatment costing a quarter million dollars annually for patients suffering from Muckle-Wells syndrome, a rare disorder characterized by occasional fever, skin rash and joint pain, according to the

Developed by Vertex Pharmaceuticals, Kalydeco is a nearly $300,000-a-year drug that treats a rare form of cystic fibrosis in patients ages 6 years and older. About 4 percent of the nearly 30,000 people in the United States with cystic fibrosis has this variant, caused by a specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene, according to the FDA.

At an estimated cost of $300,000 per year, Acthar is an expensive drug largely because insurance won't cover its use because it's not FDA-approved. Manufactured by Mallinckrodt Pharmaceuticals, the drug is used to treat seizures in infants under 2 years old.

, also known as glycogen storage disease type II, that causes an accumulation of glycogen in the body's tissues, resulting in major damage primarily to the heart and muscles. It's a rare disorder affecting about 1 in 40,000 people in the United States.
Myozyme costs $100,000 per year to treat a child and three times that to treat adults. The drug is life-saving, but carries with it the possibility heart and lung failure or allergic shock as possible side effects.

Hereditary Angioedema (HAE) afflicts between one in 10,000 and one in 50,000 Americans, causing swelling in the hands, face and throat, according to the Hereditary Angioedema Association. The condition can also cause abdominal pain, nausea and vomiting and can constrict airways enough to be fatal.
Derived from human blood, Cinryze is a $350,000-a-year medication to treat HAE.

, or Hunter syndrome, which occurs almost exclusively in males. No indications of Hunter syndrome appear at birth, but progressively develop over time, resulting in enlarged organs, constricted airways, skin abnormalities and more.

, an inherited metabolic disease that leaves the body unable to break down long chains of sugar molecules. Symptoms include abnormal bone development, coarse facial features, short stature and more.
Manufactured by BioMarin Pharmaceutical, Vimizim is a treatment approved by the FDA just last year to treat the disease at a cost of $380,000 a year.

, also known as Maroteaux-Lamy syndrome, causes the body's tissues and organs to enlarge and become scarred. The condition also often results in skeletal abnormalities, according to the U.S. National Library of Medicine, often leading to short stature and joint abnormalities that affect mobility.
Also developed by BioMarin Pharmaceutical, Naglazyme is a $485,000-per-year enzyme replacement that promotes tissue growth and joint mobility, making it easier for patients to get around.

, a disease that destroys red blood cells. Only around 8,000 Americans suffer from this condition, which can increase risk of infections and severe anemia. The drug improves quality of life, but it is not a cure, so patients with this condition need to spend around $536,000 a year for their continued treatment.
Four years ago, the FDA also approved its use for

Glybera is a drug that sets a new milestone for drug prices worldwide, the only drug on this list to cost over $1 million. A one-time series of 60 injections costs $1.21 million.
Made by UniQure, Glybera is for those coping with an extremely rare condition known as familial lipoprotein lipase deficiency, a literally one-in-a-million kind of disease. The drug is approved for use in the some 150 to 200 people with the disease in the European Union, but is not yet available in the United States.